Philippe Ruszniewski1, Juan W Valle2, Catherine Lombard-Bohas3, Daniel J Cuthbertson4, Petros Perros5, Luboš Holubec6, Gianfranco Delle Fave7, Denis Smith8, Patricia Niccoli9, Pascal Maisonobe10, Philippe Atlan10, Martyn E Caplin11. 1. Beaujon Hospital and Paris Diderot University, Clichy, France. Electronic address: philippe.ruszniewski@bjn.aphp.fr. 2. Institute of Cancer Studies, University of Manchester/The Christie NHS Foundation Trust, Manchester, UK. 3. Edouard-Herriot Hospital, Hospices Civils de Lyon, Lyon, France. 4. Department of Obesity and Endocrinology and Liverpool ENETS Centre of Excellence, University Hospital Aintree and University of Liverpool, Liverpool, UK. 5. Freeman Hospital, Newcastle-upon-Tyne, UK. 6. Teaching Hospital Plzen, Plzen-Bory, Czech Republic. 7. Ospedale Sant' Andrea, Rome, Italy. 8. Saint André Hospital, Bordeaux, France. 9. CHU Timone, Marseille, France. 10. Ipsen, Boulogne-Billancourt, France. 11. Royal Free Hospital, London, UK.
Abstract
BACKGROUND: Lanreotide Autogel/Depot effectively controls symptoms in patients with carcinoid syndrome associated with neuroendocrine tumours. Data on patient-reported outcomes are sparse. AIM: To evaluate the effect of lanreotide on patient-reported outcomes (PROs) with carcinoid syndrome. METHODS: This was an international, open-label, observational study of adults with neuroendocrine tumours and history of diarrhoea, receiving lanreotide for >3 months for relief of carcinoid syndrome symptoms. The primary PRO measure was satisfaction with diarrhoea control. Secondary PRO measures included severity, change in symptoms and impact on daily life of diarrhoea; and patient satisfaction with flushing control. RESULTS: Of 273 patients enrolled, 76% were 'completely' or 'rather' satisfied with diarrhoea control; 79% reported improvement in diarrhoea with lanreotide. The proportion of patients with 'mild', 'minimal', or 'no diarrhoea' increased from 33% before treatment to 75% during treatment; 75% were unconcerned about the impact of diarrhoea on daily life. Satisfaction with flushing control amongst patients with significant flushing at treatment initiation was 73%. CONCLUSIONS: Lanreotide treatment was associated with improvements in symptoms as well as a range of PROs in patients with neuroendocrine tumours and carcinoid syndrome (ClinicalTrials.gov: NCT01234168).
BACKGROUND: Lanreotide Autogel/Depot effectively controls symptoms in patients with carcinoid syndrome associated with neuroendocrine tumours. Data on patient-reported outcomes are sparse. AIM: To evaluate the effect of lanreotide on patient-reported outcomes (PROs) with carcinoid syndrome. METHODS: This was an international, open-label, observational study of adults with neuroendocrine tumours and history of diarrhoea, receiving lanreotide for >3 months for relief of carcinoid syndrome symptoms. The primary PRO measure was satisfaction with diarrhoea control. Secondary PRO measures included severity, change in symptoms and impact on daily life of diarrhoea; and patient satisfaction with flushing control. RESULTS: Of 273 patients enrolled, 76% were 'completely' or 'rather' satisfied with diarrhoea control; 79% reported improvement in diarrhoea with lanreotide. The proportion of patients with 'mild', 'minimal', or 'no diarrhoea' increased from 33% before treatment to 75% during treatment; 75% were unconcerned about the impact of diarrhoea on daily life. Satisfaction with flushing control amongst patients with significant flushing at treatment initiation was 73%. CONCLUSIONS: Lanreotide treatment was associated with improvements in symptoms as well as a range of PROs in patients with neuroendocrine tumours and carcinoid syndrome (ClinicalTrials.gov: NCT01234168).
Authors: George A Fisher; Edward M Wolin; Nilani Liyanage; Susan Pitman Lowenthal; Beloo Mirakhur; Rodney F Pommier; Montaser Shaheen; Aaron Vinik Journal: Oncologist Date: 2017-10-16
Authors: Rosaria M Ruggeri; Barbara Altieri; Erika Grossrubatcher; Roberto Minotta; Maria Grazia Tarsitano; Virginia Zamponi; Andrea MIsidori; Antongiulio Faggiano; Anna Maria Colao Journal: Rev Endocr Metab Disord Date: 2022-03-16 Impact factor: 6.514
Authors: Rosa Maria Paragliola; Alessandro Prete; Giampaolo Papi; Francesco Torino; Andrea Corsello; Alfredo Pontecorvi; Salvatore Maria Corsello Journal: Drug Des Devel Ther Date: 2016-10-25 Impact factor: 4.162
Authors: Caroline Martini; Eva-Maria Gamper; Lisa Wintner; Bernhard Nilica; Barbara Sperner-Unterweger; Bernhard Holzner; Irene Virgolini Journal: Health Qual Life Outcomes Date: 2016-09-10 Impact factor: 3.186